Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)